webinar

Implementing ADCC assays in QC: When donor variability isn’t an option

Supported by:

29 November 2017

Supported by:

29 November 2017

Implementing ADCC assays in QC: When donor variability isn’t an option

ABOUT THIS WEBINAR:

Inherent donor variability of immune effector cells presents a significant challenge for developing a robust and reproducible ADCC assays for QC lot release. DiscoverX recently introduced the single donor-derived KILR CD16 Effector Cells to ensure assay reproducibility for screening, characterisation, and QC lot release of antibody drugs.

The webinar focused on 2 qualification studies that were performed using these effectors to demonstrate accuracy and precision in different assay formats.

KEYNOTE SPEAKERS:

Laura Munro, Scientist, R&D and BioAnalytical Technical Services, Sartorius Stedim BioOutsource LimitedLaura Munro, Scientist, R&D and BioAnalytical Technical Services, Sartorius Stedim BioOutsource Limited

Laura’s background in immunology has provided extensive experience for her current role in developing and qualifying Bioassays and ELISAs for use in the characterisation of monoclonal antibodies.

Lisa Blackwood, Scientist, R&D and BioAnalytical Technical Services, Sartorius Stedim BioOutsource LimitedLisa Blackwood, Scientist, R&D and BioAnalytical Technical Services, Sartorius Stedim BioOutsource Limited

Lisa joined BioOutsource as an assay development scientist, responsible for development and qualification of cell-based and binding assays for biosimilar comparability and characterisation studies.

Alpana Prasad, Product Manager, Eurofins DiscoverXAlpana Prasad, Product Manager, Eurofins DiscoverX

Alpana manages DiscoverX’s biologics & immuno-oncology products, and has extensive experience in marketing life sciences products & biosimilars. She has a PhD in Biochemistry from University of Oxford.

Send this to a friend